10D

10D is a Tel Aviv-based early-stage venture firm investing across digital health, fintech, insurance, computer vision, and AI-driven companies with seed and Series A check sizes typically in the one to five million dollar range. The firm operates inside the Israeli technology ecosystem, where the density of computer vision and applied AI engineering talent has made the country a meaningful global node for AI-native startups. In healthcare, 10D’s positioning sits at the intersection of digital health and AI-in-healthcare, where Israeli founders have built a track record of producing computer-vision-based diagnostic and clinical decision support companies that scale internationally despite the small size of the domestic Israeli market. For Israeli healthcare founders raising at seed or Series A, 10D represents one of the active local funds with explicit AI focus and a check size that can lead or co-lead first institutional rounds.

The investment thesis is broader than healthcare alone, spanning fintech, insurance, computer vision, and AI applications, but the digital health and AI-in-healthcare focus is genuine and consistent with the firm’s stated areas of investment. The Israeli AI ecosystem produces particularly strong companies in computer vision applied to medical imaging, in machine learning applied to clinical workflows, and in data infrastructure for healthcare and insurance. 10D’s cross-vertical thesis across fintech, insurance, and healthcare is informative because it signals a willingness to engage with regulated industries broadly, where Israeli founders have to contend with complex compliance and data-privacy environments and where the firm’s pattern matching across regulated verticals can be useful. Founders should expect diligence to probe technical depth, particularly on the AI substrate, and to engage with the question of how an Israeli company can scale internationally given the small size of the local market.

This profile does not include a specific list of portfolio companies. Founders should consult 10D’s portfolio page and pay attention to which healthcare and AI-driven investments have progressed from seed through Series A and beyond inside the portfolio. The progression pattern reveals which subsectors the partnership has built genuine conviction in. Founders should also identify which portfolio companies have established US or European commercial presence, since international expansion is essentially required for Israeli companies to reach venture-scale outcomes given the limited domestic market.

The one to five million dollar check size range positions 10D as a meaningful seed and Series A participant. At seed, the firm can lead or co-lead with a check sized to anchor the round. At Series A, 10D typically participates alongside larger institutional leads, often international funds entering the Israeli market or larger Israeli venture firms. Founders should plan their cap table assuming 10D will participate in follow-on rounds to the extent reserves permit, while understanding that the international scaling pattern of Israeli companies often requires US-based lead investors at later stages. The fund syndicates with other Israeli early-stage investors, with international funds with established Israeli investment programs, and with corporate venture arms of major US and European technology companies that have built Israel-focused investment teams.

Team member names are not enumerated in the source data for this profile. Founders should consult 10D’s website to identify the current investing team and pay particular attention to which partners have prior operating or technical experience in computer vision, machine learning, or healthcare versus which come from financial backgrounds. Decision-making is partnership-driven, and the cycle from first meeting to term sheet at Israeli early-stage funds is generally faster than at comparable US funds, partly because the partnership is geographically concentrated and partly because the Israeli venture market operates at higher velocity.

The most reliable path into 10D is a warm introduction from a portfolio founder, from another Israeli early-stage investor, or from a known operator in the Tel Aviv technology community. The Israeli venture ecosystem is dense and well-networked, and partner-level introductions through trusted channels are the dominant origination pathway. Connections through the Israeli military technology community, particularly through Unit 8200 alumni networks, carry meaningful weight given the firm’s AI focus and the over-representation of those networks among Israeli technical founders. Cold inbound through the firm’s website is read and occasionally converts, particularly when the founder can demonstrate technical depth in the first message.

Founders should approach 10D when they are an Israeli digital health, AI-in-healthcare, or computer-vision-based clinical company at seed or Series A and when the founding team has technical depth and a credible plan for international expansion. The firm is not the right fit for non-Israeli companies, for late-stage growth rounds, or for digital health companies whose go-to-market depends primarily on the Israeli domestic market without meaningful international expansion plans. It is a good fit for Israeli healthcare AI companies with computer-vision or machine-learning core technology, for digital health platforms with international scaling potential, and for founders who value local Israeli network depth as a complement to international capital at subsequent stages.